539 related articles for article (PubMed ID: 29427492)
1. Future therapy for non-alcoholic fatty liver disease.
Issa D; Patel V; Sanyal AJ
Liver Int; 2018 Feb; 38 Suppl 1():56-63. PubMed ID: 29427492
[TBL] [Abstract][Full Text] [Related]
2. Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
Banini BA; Sanyal AJ
Curr Opin Gastroenterol; 2017 May; 33(3):134-141. PubMed ID: 28346237
[TBL] [Abstract][Full Text] [Related]
3. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic fatty liver disease: a systematic review.
Rinella ME
JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
[TBL] [Abstract][Full Text] [Related]
5. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Golabi P; Bush H; Younossi ZM
Clin Liver Dis; 2017 Nov; 21(4):739-753. PubMed ID: 28987260
[TBL] [Abstract][Full Text] [Related]
6. Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?
Sundaram V; Morgan TR
Clin Liver Dis; 2019 Feb; 23(1):157-165. PubMed ID: 30454829
[TBL] [Abstract][Full Text] [Related]
7. Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease.
Patel SS; Siddiqui MS
Drugs; 2019 Jan; 79(1):75-84. PubMed ID: 30588564
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic landscape of non-alcoholic steatohepatitis.
Perazzo H; Dufour JF
Liver Int; 2017 May; 37(5):634-647. PubMed ID: 27727520
[TBL] [Abstract][Full Text] [Related]
9. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
10. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
11. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
Corey KE; Rinella ME
Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
[TBL] [Abstract][Full Text] [Related]
12. Practical approach to non-alcoholic fatty liver disease in patients with diabetes.
Tai FW; Syn WK; Alazawi W
Diabet Med; 2015 Sep; 32(9):1121-33. PubMed ID: 25683343
[TBL] [Abstract][Full Text] [Related]
13. [Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis].
Heebøll S; Kazankov K; Poulsen MK; Vilstrup H; Grønbæk H
Ugeskr Laeger; 2012 Feb; 174(8):488-90. PubMed ID: 22348670
[TBL] [Abstract][Full Text] [Related]
14. Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter.
Cha JY; Park JM; Lee HJ; Bae JS; Han YM; Oh BC; Ko KH; Hahm KB
Curr Pharm Des; 2017; 23(27):3941-3951. PubMed ID: 28714405
[TBL] [Abstract][Full Text] [Related]
15. State of the art: treatment of nonalcoholic steatohepatitis.
Pearlman M; Loomba R
Curr Opin Gastroenterol; 2014 May; 30(3):223-37. PubMed ID: 24717764
[TBL] [Abstract][Full Text] [Related]
16. Management and diagnosis of fatty liver disease.
Schneier AT; Citti CC; Dieterich DT
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):671-83. PubMed ID: 25716275
[TBL] [Abstract][Full Text] [Related]
17. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
Clemente MG; Mandato C; Poeta M; Vajro P
World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
[TBL] [Abstract][Full Text] [Related]
18. [Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016].
Pár A; Pár G
Orv Hetil; 2016 Jun; 157(25):987-94. PubMed ID: 27287838
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients.
Cheung A; Figueredo C; Rinella ME
Am J Gastroenterol; 2019 Apr; 114(4):579-590. PubMed ID: 30839326
[TBL] [Abstract][Full Text] [Related]
20. Current treatment for non-alcoholic fatty liver disease.
Moctezuma-Velázquez C
Rev Gastroenterol Mex (Engl Ed); 2018; 83(2):125-133. PubMed ID: 29655574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
